In summary, although deal volume is down, there are fewer but larger deal sizes. Life sciences companies that can demonstrate ...

Meanwhile at SpinCo, a new spinoff of Galapagos, Henry Gosebruch was appointed CEO. Gosebruch was previously president and ...

As has been widely reported on, immunisation rates, including for flu and RSV, have been falling – at a troubling rate – and ...

Roche's Itovebi was the first PI3K inhibitor to get approved as a first-line treatment for breast cancer last year – and new ...

In particular, the organisation is unhappy with Kennedy's repeated assertions that Alzheimer's research has been dedicated to ...

Final draft guidance from NICE has backed NHS use of Filspari (sparsentan) for primary immunoglobulin A nephropathy (IgAN), ...

While not the first biologic to break into the COPD sector – Sanofi and Regeneron took that crown with the approval of their ...

Shares in the digital therapeutics (DTx) developer closed up more than 17% after its debut on the NYSE at $32 under the HNGE ...

Threshold Pharma is to go ahead with Phase 3 clinical trials of its only drug, TH-302, despite recent Phase 2 trials failing to show statistically significant improvement in overall survival.

Gilead Sciences has joined the list of pharma groups hiking their capital investment plans in the US, adding $11 billion in new spending as the industry prepares for potential sector-specific tariffs.

The European Commission has announced a €500 million ($566 million) initiative to convince top scientific talent from around the world to base their teams within the EU, including US researchers ...

To remain relevant in an interconnected ecosystem, biopharma must go beyond optimising yesterday’s markets and begin ...